{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T04:10:10Z","timestamp":1749183010808,"version":"3.41.0"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>Serotonin syndrome is a rare, life-threatening toxidrome caused by serotonergic agents. This syndrome classically presents with a combination of mental status changes, autonomic hyperactivity, and neuromuscular abnormalities. However, diagnosing the condition is difficult because of its variable symptoms at presentation. As a result, serotonin syndrome often is underreported, making it harder to understand, recognize, and treat. Patients with this condition may present to primary or urgent care or an ED, and may become acutely symptomatic during an inpatient admission. Clinicians must be able to identify at-risk patients and intervene to prevent potentially lethal complications.<\/jats:p>","DOI":"10.1097\/01.jaa.0000000000000087","type":"journal-article","created":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T15:02:34Z","timestamp":1724166154000},"page":"21-26","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Serotonin syndrome"],"prefix":"10.1097","volume":"37","author":[{"given":"Daniel","family":"Mungul","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Bila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace","family":"Petr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie","family":"Satterberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alyssa","family":"Knueven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,8,27]]},"reference":[{"author":"Bamalan","key":"R1-20250605"},{"author":"Simon","doi-asserted-by":"crossref","article-title":"Serotonin syndrome","key":"R2-20250605","DOI":"10.1007\/978-3-319-99124-5_270"},{"issue":"4","key":"R3-20250605","doi-asserted-by":"crossref","first-page":"719","DOI":"10.31083\/j.jin.2020.04.314","article-title":"Serotonin syndrome: a clinical review of current controversies","volume":"19","author":"Werneke","year":"2020","journal-title":"J Integr Neurosci"},{"issue":"5","key":"R4-20250605","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1001\/jamaneurol.2017.5144","article-title":"Association of coprescription of triptan antimigraine drugs and selective serotonin reuptake inhibitor or selective norepinephrine reuptake inhibitor antidepressants with serotonin syndrome","volume":"75","author":"Orlova","year":"2018","journal-title":"JAMA Neurol"},{"key":"R5-20250605","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jcrc.2020.12.014","article-title":"The prevalence of serotonin syndrome in an intensive care unit: a prospective observational study","volume":"63","author":"Prakash","year":"2021","journal-title":"J Crit Care"},{"issue":"11","key":"R6-20250605","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMra041867","article-title":"The serotonin syndrome","volume":"352","author":"Boyer","year":"2005","journal-title":"N Engl J Med"},{"key":"R7-20250605","first-page":"12","article-title":"Serotonin syndrome: pathophysiology, clinical features, management, and potential future directions","author":"Scotton","year":"2019","journal-title":"Int J Tryptophan Res"},{"issue":"9","key":"R9-20250605","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.3390\/ijms20092288","article-title":"The serotonin syndrome: from molecular mechanisms to clinical practice","volume":"20","author":"Francescangeli","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"1","key":"R10-20250605","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/15563650.2022.2151455","article-title":"Predicting serotonin toxicity in serotonin reuptake inhibitor overdose","volume":"61","author":"Cooper","year":"2023","journal-title":"Clin Toxicol (Phila)"},{"issue":"1","key":"R11-20250605","doi-asserted-by":"crossref","first-page":"52","DOI":"10.4103\/aian.AIAN_344_18","article-title":"Refining the clinical features of serotonin syndrome: a prospective observational study of 45 patients","volume":"22","author":"Prakash","year":"2019","journal-title":"Ann Indian Acad Neurol"},{"issue":"4","key":"R12-20250605","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.amjopharm.2007.12.002","article-title":"Polypharmacy in elderly patients","volume":"5","author":"Hajjar","year":"2007","journal-title":"Am J Geriatr Pharmacother"},{"issue":"9","key":"R13-20250605","first-page":"e10635","article-title":"The genetic foundations of serotonin syndrome, neuroleptic malignant syndrome, and malignant hyperthermia: is there a genetic association between these disorders","volume":"12","author":"Ortiz","year":"2020","journal-title":"Cureus"},{"issue":"2","key":"R14-20250605","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/FPC.0000000000000392","article-title":"PharmGKB summary: sertraline pathway, pharmacokinetics","volume":"30","author":"Huddart","year":"2020","journal-title":"Pharmacogenet Genomics"},{"issue":"3","key":"R15-20250605","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2165\/00003088-199426030-00004","article-title":"Clinical pharmacokinetics of fluoxetine","volume":"26","author":"Altamura","year":"1994","journal-title":"Clin Pharmacokinet"},{"key":"R16-20250605","doi-asserted-by":"crossref","first-page":"g1626","DOI":"10.1136\/bmj.g1626","article-title":"Serotonin syndrome","volume":"348","author":"Buckley","year":"2014","journal-title":"BMJ"},{"issue":"11","key":"R17-20250605","doi-asserted-by":"crossref","first-page":"810","DOI":"10.3949\/ccjm.83a.15129","article-title":"Serotonin syndrome: preventing, recognizing, and treating it","volume":"83","author":"Wang","year":"2016","journal-title":"Cleve Clin J Med"},{"issue":"4","key":"R18-20250605","first-page":"533","article-title":"Serotonin syndrome","volume":"13","author":"Volpi-Abadie","year":"2013","journal-title":"Ochsner J"},{"issue":"9","key":"R19-20250605","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/qjmed\/hcg109","article-title":"The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity","volume":"96","author":"Dunkley","year":"2003","journal-title":"QJM"},{"issue":"4","key":"R20-20250605","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/00005792-200007000-00001","article-title":"Serotonin syndrome. Presentation of 2 cases and review of the literature","volume":"79","author":"Mason","year":"2000","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"R21-20250605","doi-asserted-by":"crossref","first-page":"17r02185","DOI":"10.4088\/PCC.17r02185","article-title":"Neuroleptic malignant syndrome: diagnosis and management","volume":"20","author":"Ware","year":"2018","journal-title":"Prim Care Companion CNS Disord"},{"issue":"4","key":"R22-20250605","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ccc.2012.07.008","article-title":"Toxidromes","volume":"28","author":"Holstege","year":"2012","journal-title":"Crit Care Clin"},{"issue":"5","key":"R23-20250605","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jopan.2017.04.008","article-title":"Malignant hyperthermia: a review","volume":"33","author":"Mullins","year":"2018","journal-title":"J Perianesth Nurs"},{"issue":"3","key":"R24-20250605","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/0885066613498053","article-title":"Thyroid storm: an updated review","volume":"30","author":"Chiha","year":"2015","journal-title":"J Intensive Care Med"},{"author":"Lewis","article-title":"Dystonic reactions","key":"R25-20250605"},{"issue":"7","key":"R26-20250605","first-page":"988","article-title":"Recognition and treatment of serotonin syndrome","volume":"54","author":"Frank","year":"2008","journal-title":"Can Fam Physician"},{"issue":"3","key":"R27-20250605","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10286-018-0545-8","article-title":"Autonomic dysfunction in the neurological intensive care unit","volume":"29","author":"Hilz","year":"2019","journal-title":"Clin Auton Res"},{"author":"Pierre","article-title":"Arterial lines","key":"R28-20250605"},{"issue":"21","key":"R29-20250605","doi-asserted-by":"crossref","DOI":"10.1503\/cmaj.211966","article-title":"Administration of vasopressors through peripheral venous catheters","volume":"194","author":"Araiza","year":"2022","journal-title":"Can Med Assoc J"},{"issue":"4","key":"R30-20250605","first-page":"603","article-title":"Serotonin toxicity and malignant hyperthermia","volume":"88","author":"Isbister","year":"2002","journal-title":"Br J Anaesth"},{"issue":"3","key":"R31-20250605","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1161\/CIRCULATIONAHA.115.017350","article-title":"How to stay cool in the intensive care unit","volume":"132","author":"Polderman","year":"2015","journal-title":"Circulation"},{"issue":"2","key":"R32-20250605","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0197-0186(02)00213-9","article-title":"Diazepam and chlormethiazole attenuate the development of hyperthermia in an animal model of the serotonin syndrome","volume":"43","author":"Nisijima","year":"2003","journal-title":"Neurochem Int"},{"issue":"7-8","key":"R33-20250605","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1345\/aph.10203","article-title":"Serotonin syndrome: early management with cyproheptadine","volume":"35","author":"McDaniel","year":"2001","journal-title":"Ann Pharmacother"},{"issue":"1","key":"R34-20250605","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1177\/026988119901300111","article-title":"The serotonin syndrome and its treatment","volume":"13","author":"Gillman","year":"1999","journal-title":"J Psychopharmacol"},{"issue":"5","key":"R35-20250605","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0735-6757(03)00088-3","article-title":"2002 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System","volume":"21","author":"Watson","year":"2003","journal-title":"Am J Emerg Med"},{"author":"Zoppi","article-title":"Half-life and withdrawal symptoms of antidepressants","key":"R36-20250605"},{"issue":"2","key":"R37-20250605","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/15563650.2021.1993242","article-title":"The serotonin toxidrome: shortfalls of current diagnostic criteria for related syndromes","volume":"60","author":"Chiew","year":"2022","journal-title":"Clin Toxicol (Phila)"}],"container-title":["JAAPA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/01.JAA.0000000000000087","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T20:02:10Z","timestamp":1749153730000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/01.JAA.0000000000000087"}},"subtitle":["A rare yet crucial diagnosis"],"short-title":[],"issued":{"date-parts":[[2024,8,27]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/01.jaa.0000000000000087","relation":{},"ISSN":["1547-1896","0893-7400"],"issn-type":[{"type":"print","value":"1547-1896"},{"type":"electronic","value":"0893-7400"}],"subject":[],"published":{"date-parts":[[2024,8,27]]}}}